Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 43.24B +108.2% |
| Revenue (ttm) | 45.87B -1.9% |
| Net Income | -198.00M |
| EPS | -0.20 |
| Shares Out | 982.42M |
| PE Ratio | n/a |
| Forward PE | 8.41 |
| Dividend | 0.11 (0.25%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 3,881,987 |
| Average Volume | 4,101,053 |
| Open | 43.80 |
| Previous Close | 44.02 |
| Day's Range | 43.20 - 44.66 |
| 52-Week Range | 18.38 - 46.74 |
| Beta | 0.89 |
| RSI | 64.21 |
| Earnings Date | Feb 25, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign.
Bayer to build new canola research and development site in Winnipeg
Bayer says it will put more than $45 million toward building a new research and development facility in Winnipeg.
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada's leadership in canola innovation by establishing a cutting-edge...
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
BERLIN--(BUSINESS WIRE)--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two...
Bayer Announces FDA's Orphan Drug Designation For OpCT-001 To Treat Retinitis Pigmentosa
(RTTNews) - Bayer AG (BYR.L, BAY.MI, BAYN.DE) and its independently operated subsidiary BlueRock Therapeutics LP announced that its investigational cell therapy, OpCT-001, has received Orphan Drug Des...
Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case
BAYRY jumps 6.4% after the Supreme Court agrees to review the Durnell Roundup case, a key test of federal preemption in glyphosate litigation.
EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
BERLIN & NASHVILLE, Tenn.--(BUSINESS WIRE)--Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innova...
Bayer: Timing Upside In 2025, More Upside Possible But Risky In 2026E (Downgrade)
Bayer Shares Rise After U.S Supreme Court Agrees to Review Roundup Case
Bayer : U.S. Supreme Court To Review Durnell Case In Roundup Litigation
(RTTNews) - Bayer announced that the U.S. Supreme Court has agreed to review the Durnell case in the ongoing Roundup litigation. The Court's decision follows a petition filed by Monsanto in April 2025...
Supreme Court to hear Bayer's appeal to block thousands of Roundup weedkiller lawsuits
Bayer is arguing that consumers should not be able to sue it under state law for failing to warn that Roundup increases cancer risk because the Environmental Protection Agency has found no such risk a...
Bayer (BAYZF) Sees 5% Gain as U.S. Supreme Court Agrees to Hear Roundup Appeal
Bayer (BAYZF) Sees 5% Gain as U.S. Supreme Court Agrees to Hear Roundup Appeal
Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup litigation
The U.S. Supreme Court today announced that it will review the Durnell Roundup case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circui...
Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation
LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in ...
Supreme Court takes up Bayer’s bid to limit Roundup weedkiller liability
The Supreme Court on Friday took up a bid from Bayer to limit liability for pesticide makers, including Bayer’s Roundup weedkiller, which has become the subject of numerous cancer suits. The court sai...
Bayer gains after U.S. Supreme Court grants hearing on Roundup suits
Bayer (BAYZF) shares jump after Supreme Court agrees to hear Roundup appeal, impacting 67,000 lawsuits.
Supreme Court to Hear Bayer's Challenge to Roundup Weedkiller Cases
High court gives company hope in its effort to mitigate long-running litigation that has cost it billions of dollars.
US Supreme Court to hear Bayer's bid to curb Roundup cases
The U.S. Supreme Court agreed on Friday to hear Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and potentially avert billions of dollars in damages.
Winter woes? Fatigue and body aches lead common complaints
Body aches (28%), fatigue (26%), feeling “off” (23%) and a runny nose (21%) are the four horsemen of a subpar day, according to new research. A survey of 2,000 adults conducted by Talker Research for ...
Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug
DAX Slips After Hitting New Record High; Bayer, RWE Post Strong Gains
(RTTNews) - German stocks climbed higher Wednesday morning with investors reacting to some encouraging corporate updates, and robust trade data from China that showed the resilience of the manufacturi...
Bayer AG at JPMorgan Healthcare Conference Transcript
Bayer AG at JPMorgan Healthcare Conference Transcript
Bayer targets return to mid-single-digit pharma growth by 2027
The pharmaceuticals and agriculture group Bayer aims to return its pharmaceuticals business to mid-single-digit percentage growth by no later than 2027 and lift operating margins to about 30% by 2030,...